The density of striatal dopamine D2 receptors has been shown to vary considerably among healthy subjects.
Positron emission tomography (PET) has been used to demonstrate a considerable variability of dopamine D2 receptor density in healthy subjects in vivo. 1 This variability has recently been associated with the personality trait Detachment, 5 indicating that dopamine D2 receptor density may have functional importance for personality characteristics in human subjects. A fundamental issue is the extent to which the dopamine D2 receptor variability is due to environmental influences or genetic contributions. A number of environmental influences such as antipsychotic medication, 6 age 7-9 and menstrual phases 10 have been suggested to alter dopamine D2 receptor density. Low dopamine D2 receptor binding in subjects with alcohol, 11, 12 cocaine, 13, 14 and opiate 15 dependence may suggest that these drugs also have an effect on D2 receptor density. However, the degree to which these factors may alter the receptor density cannot explain the two to threefold variability seen among healthy subjects. 1 Animal data suggest a genetic contribution to the variation in dopamine receptor density. Differences in dopamine D2 receptor-binding characteristics between different inbred mice and rat strains have been repeatedly confirmed. [16] [17] [18] [19] [20] [21] [22] [23] [24] In inbred mice strains a genome-wide search for catalepsy-related genes using a quantitative trait loci approach detected a locus near or at the DRD2. 25 Therefore, also in humans several attempts have been performed searching for associations between dopamine D2 receptor polymorphisms and different measures of dopaminergic binding parameters or glucose metabolism in brain regions containing dopaminergic innervation (Table 1) .
In a recent PET investigation of Finnish healthy individuals the DRD2 TaqIA1 allele, suggested to be connected with alcoholism, 26 was associated with reduced striatal D2 receptor availability. 3 So far there is no evidence that the DRD2 TaqIA polymorphism has a functional role. It has rather been assumed that the relationships obtained between the DRD2 TaqIA polymorphism and phenotype data are due to linkage disequilibrium between the DRD2 TaqIA polymorphism and another adjacent functional polymorphism. The same Finnish research group has previously screened healthy volunteers for possible exonic polymorphisms altering the amino acid composition of the protein in the DRD2 gene. 27 No evidence emerged that these infrequent polymorphisms significantly influence dopamine D2 receptor density.
In the present study, we analyzed a recently described putative functional DRD2 promoter polymorphism (−141C Ins/Del) and two other common DRD2 polymorphisms (TaqIB, intron 2 STRP) for possible relationships to striatal dopamine D2 receptor density in vivo. We also attempted to replicate the previous findings of reduced DRD2 binding properties in subjects carrying the TaqIA1 allele. The 56 subjects were evaluated as healthy at the time of positron emission tomography with the radioligand [ 11 C] raclopride 1 (see cover figure) . Dopamine D2 receptor binding was expressed as the ratio of bound to free (B/F) radioligand at time of transient equilibrium. 28 The DRD2 −141C Ins/Ins genotype was the most frequent (76.8%), followed by the Ins/Del (19.6%) and Del/Del (3.6%) genotypes. The −141C Ins/Del allele frequencies were 0.87 (Ins) and 0.13 (Del), respectively. The DRD2 −141C Ins/Del polymorphism was not in linkage disequilibrium with the TaqIA ( (Table 2 ). When the sample was subdivided by gender a similar but non-significant distribution was obtained for men (t = 1.62, d.f. = 41, P = 0.113). Among the women only one subject was a carrier of the Ins/Del genotype (t = 1.47, d.f. = 11, P = 0.169).
The DRD2 TaqIA genotype frequencies were 3.5% (A1A1), 28.6% (A1A2) and 67.9% (A2A2), respectively. The allele frequencies were 0.20 (A1) and 0.80 (A2), respectively. The TaqIA polymorphism was in linkage disequilibrium with the TaqIB polymorphism (
There was a significant association (t = −2.58, d.f. = 54, P = 0.013) between the presence of the A1 allele and striatal [
11 C]raclopride binding potential, with lower mean B/F ratios in subjects with the A1A1 (3.46) and A1A2 (3.55) genotypes than the A2A2 (3.98) genotype, respectively ( Table 2) .
The DRD2 TaqIB genotype frequencies were 3.5% Table 2 Relationships between dopamine D2 receptor polymorphisms and estimated striatal dopamine receptor density (B/Fratio) in healthy human subjects (n = 56) 16-repeat) , respectively. There were no significant differences when B/F ratios in subjects carrying any of the four alleles were compared vs B/F ratios in subjects without this allele (Table 2) .
In the total sample there was a significant relationship between the DRD2 promoter −141C Ins/Del polymorphism and striatal dopamine receptor density. This is of interest as the different alleles in this polymorphism have been shown to differ with regard to in vitro luciferase activity in Y-79 and 293 cells. 29 Our results indicate that the −141C Ins/Del polymorphism influences dopamine D2 receptor density and thus may be of functional importance in vivo.
When the TaqIA polymorphism was compared vs dopamine D2 receptor binding data, a difference emerged indicating lower binding potential in subjects carrying the A1 allele. The direction of the changes is in agreement with one previous PET and two post mortem studies [2] [3] [4] (Table 1) . The results may also possibly be interpreted as in line with those of Noble et al, 30 who reported lower glucose metabolism in putamen and several other cortical areas with dopaminergic innervation. The results are, however, at variance with an American single positron emission computerized tomography (SPECT) study where no association was found between the DRD2 TaqlA or TaqIB polymorphisms and dopamine receptor binding. 31 Possible reasons for the inability of the American SPECT study to replicate the relationship may include the ethnical or clinical composition of the subject groups investigated as well as the different methodology used. The reliability of [
11 C]raclopride binding is high as demonstrated by test-retest analyses. 32, 33 Considering that the SPECT radioligand [
123 I]IBZM gives a lower signal than [ 11 C]raclopride and the relatively low resolution of SPECT, it is likely that the reliability is not as high as for the PET studies. Lower reliability may account for higher variability and also hamper the demonstration of the associations reported in the present study. Thus, the SPECT study may be a false negative. Another possibility is that the two postmortem studies, 2,4 the Finnish, 3 and the present PET study reflect type II errors, although this at present seems less likely. However, all published studies are small from a statistical point of view. In particular none of the studies have the power to adequately assess the effect of the homozygotic genotypes. For such an assessment thousands of individuals should be screened with regard to dopamine receptor genotypes. Then subjects homozygotic for the −141C Del, TaqIA1 and TaqIB1 alleles, respectively, at a number of around 25-30 should be recruited for PET experiments to form a group for comparison with equal numbers of heterozygotic and non-carriers of these alleles.
The relationships between both the −141C Ins/Del and TaqIA and B polymorphisms with striatal dopamine D2 receptor density may be interpreted in several ways. In agreement with previous studies, 29, 34 no linkage disequilibrium was found between the TaqIA polymorphism and the promoter −141C Ins/Del polymorphism in the present study. Therefore, if both the associations between the −141C Ins/Del and the TaqI polymorphisms and dopamine receptor density are 'real', it is possible that there may be two loci in the DRD2 gene or its surroundings that may control dopamine receptor density, one of them being the −141C Ins/Del polymorphism and the other being a yet unidentified functional polymorphism in linkage disequilibrium with the TaqIA and TaqIB polymorphisms.
The caveats of the present study include a wide age range. However, no significant influence of dopamine D2 receptor density by age was detected in this sample (r = 0.0089, P = 0.949), possibly due to a large majority of subjects within a relatively narrow age range. In the present study menstrual phases were not recorded in women. However, a recent PET-study indicates that there is no evident effect of menstrual phases on D2 receptor density. 35 Moreover, although large to comprise a human sample investigated by PET, the present sample is small from a statistical point of view.
The present results suggest that a potential functional DRD2 promoter polymorphism influences dopamine receptor density. The data also partly replicate previous studies of an association between the TaqIA polymorphism and dopamine receptor density. This indicates that genetic variation in the DRD2 gene may underlie part of the dopamine receptor variability seen in healthy human subjects. However, because of the small sample sizes in the present and previous studies and the still uncertain significance of the DRD2 polymorphisms investigated, there is need for further verification in independent samples.
Methods

Subjects
Caucasian individuals (n = 56) were recruited predominantly among students or hospital staff. Before the PET investigation all subjects were interviewed regarding physical and mental health. All subjects were also physically examined. Routine laboratory examination of blood and urine as well as computerized tomography (CT) or magnetic resonance imaging (MRI) of the head was performed. All subjects were considered to be healthy. Twenty-two months to 12 years later (mean ± SD: 6.46 ± 2.30 years) a structured interview 36 was performed by a psychiatrist (EJ) to re-assess psychiatric morbidity according to DSM-III-R, 37 somatic illness, and presence of mental and nervous system disorders among relatives. Subjects were also asked for alcohol consumption during the preceeding month and completed a questionnaire regarding tobacco habits. Hospital records were obtained and examined for diagnosis. Genealogical data for antecedents up to the third degree were obtained from parish registers to assess the origin of the individuals. At the second interview blood was drawn for molecular genetic analysis.
Of the subjects 43 were men and 13 women. The age range at the time of the second interview was 25-83 years, with a mean (±SD) of 38.5 (±12.1) years. The mean age (±SD) at PET was 32.3 (±12.2) years, age range 19-77. Nineteen were university graduates. All participants were drug-free at PET. Genealogical data indicated that 85.1% and 4.8% of the chromosomes originated in ancestors born in Sweden and Finland, respectively, and the remaining 10.1% were distributed in seven European countries and the USA. One subject had paternal ancestors of western European origin born in the USA.
Positron emission tomography
Subjects were investigated with the radioligand [ 11 C] raclopride using the Scanditronix PC 384-7B (n = 25) or PC 2048-15B (n = 31) PET systems, respectively, as previously described.
1,28,38-40 The two PET systems do not have the same performance. 41, 42 To achieve comparable results for the two different PET systems, B/Fratios obtained with the Scanditronix 384-7B were multiplied by 1.14 according to a previously published comparative study. 32 To avoid a possible influence from dopamine D3 receptors in the nucleus accumbens the ventral striatum was not included in the region of interest.
Genotype analyses
Venous blood was taken from all individuals into EDTA-containing tubes. DNA isolation 43 and genotyping procedures were as previously described. 29, 44, 45 Data analysis t-Tests were used for comparisons between genotype clusters and B/F-ratios. Due to the small number of Del/Del, A1A1, and B1B1 subjects, we classified subjects into Del carriers (Del/Del and Del/Ins), A1 carriers (A1A1 and A1A2), and B1 carriers (B1B1 and B1B2), respectively. Similarly, comparisons with regard to the DRD2 STRP-polymorphism were performed with subjects carrying the 13-repeat allele vs those without this allele, subjects carrying the 14-repeat allele vs those without this allele, etc. Chi-square tests were used for comparisons of linkage disequilibrium. Significance level was defined as a P-value less than 0.05.
